

The following listing of claims replaces all prior claims presented in the applicaiton:

14. (Previously presented) A monoclonal antibody which is free-end specific for the free N-terminus of an amyloid β -peptide, which antibody does not bind to the amyloid β -precursor protein which said amyloid β -peptide may be proteolytically derived.

23. (Previously presented) A single chain antibody, which is free-end specific for the free N-terminus or free C-terminus of an amyloid β -peptide, which antibody does not bind to the amyloid β -precursor protein which said amyloid β -peptide may be proteolytically derived.

25. (Previously presented) A single chain antibody in accordance with claim 23, which is free-end specific for the free C-terminus of an amyloid β -peptide.

33. (Previously presented) A monoclonal antibody in accordance with claim 14, which is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40, which antibody does not bind to the amyloid β -precursor protein which said amyloid β peptide may be proteolytically derived.

34. (Previously presented) A monoclonal antibody free-end specific for the free C-terminus of the amyloid β peptide A β 1-43, which antibody does not bind to the amyloid β -precursor protein which said amyloid β -peptide may be proteolytically derived.

36. (Previously presented) A single chain antibody in accordance with claim 25, which is free-end specific for the free C-terminus of amyloid β -peptide A β 1-40.

37. (Previously presented) A single chain antibody in accordance with claim 23, which is free-end specific for the free C-terminus of amyloid β -peptide A β 1-43.